Bergen, 1. november 2007: NorDiag had sales revenues of NOK 2.8 million and other revenues of NOK 1.9 million in Q3-07, compared with NOK 1.2 million and NOK 0.3 million in same quarter 2006. Sales revenues in Q2 07 were NOK 3.4 million and other revenues were NOK 1.2 million. EBITDA was NOK - 12.2 million in the third quarter, compared with an EBITDA of NOK - 7.2 million in the third quarter 2006. EBITDA in Q2 07 was NOK - 14.5 million.

Bergen, 1. november 2007: NorDiag had sales revenues of NOK 2.8 million and other revenues of NOK 1.9 million in Q3-07, compared with NOK 1.2 million and NOK 0.3 million in same quarter 2006. Sales revenues in Q2 07 were NOK 3.4 million and other revenues were NOK 1.2 million. EBITDA was NOK - 12.2 million in the third quarter, compared with an EBITDA of NOK - 7.2 million in the third quarter 2006. EBITDA in Q2 07 was NOK - 14.5 million. The cash balance was NOK 46.9 million end of Q3 07.

The decrease in sales revenue compared with the previous quarter reflects that the reimbursement of the Genefec II test was discontinued and as a consequence of the uncertainty introduced, NorDiag decided together with its distributor to withdraw the test from the market. The increase of `Other revenues` stems from higher revenues from the Infectious diseases area.

Due to the discontinuation of the Genefec test, restructuring has been carried out in the Cancer Business, reducing the number of man year with 10.5. Restructuring costs related to this in the quarter was NOK 2.7 million. The restructuring will have full effect from Q4 07.

The Infectious Diseases business had high activity and progressed well in the quarter. The development of a new low throughput instrument was finished and the product is ready for market introduction in Q4 07. On the marketing side, the company is taking steps towards international launch of products both in Europe and US.

The Cancer Business concluded the German clinical study in the quarter. Due to planned publishing in medical journal, the specific data will not be released now. However, the study has given important input to a strategic adjustment in the business area. Genefec markers in combination with competing technology gave high sensitivity and specificity.

Says Mårten Wigstøl, CEO in NorDiag, `NorDiag has developed from being a `one product company` to a company with several products in different segments. Despite being in different stages of its product lifecycle, several of these products have the capability to contribute substantially to future growth. Similar to what we have done in the business unit infectious disease - we are now taking more of a collaborative approach in the business unit cancer.`

Full report for Q3 2007 is attached.

About NorDiag ASA:
NorDiag is a biotechnology company with focus on gene based diagnostics in the fields of cancer and infectious diseases. The Company`s first product in cancer diagnosis is Genefec TM for diagnosis of colorectal cancer. The company has other applications for diagnosis of cancer under development, among others a screening product for colorectal cancer. In addition the company has a product for automated sample preparation of sexually transmitted diseases, as well as applications for other infectious diseases in the product pipeline

Contact:
CEO Mårten Wigstøl, morten.wigstol@nordiag.com, +47 91165775

Read report and presentation